Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hypoglycemia × pasireotide × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 4 Gastro-enteropancreatic neuroendocrine tumor 3 Carcinoid Tumor 2 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Pituitary ACTH Hypersecretion 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Hypoglycemia 1 Dumping Syndrome 1 Carcinoma 1 Adenoma, Islet Cell 1 Acromegaly 1

Interventions

pasireotide 1 Diazoxide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡